AAPL 219.385 0.6815% MSFT 368.125 -2.8181% NVDA 104.65 -4.5774% GOOGL 151.81 -1.6329% GOOG 153.5424 -1.6132% AMZN 185.6 -3.6945% META 562.118 -2.5353% AVGO 162.44 -3.9499% LLY 804.38 -2.2042% TSLA 248.55 -5.6915% TSM 163.325 -1.1649% V 341.81 -0.3033% JPM 240.93 -0.7906% UNH 523.0 1.3487% NVO 67.85 -0.5144% WMT 86.585 1.6853% LVMUY 123.35 -2.4747% XOM 119.62 1.6054% LVMHF 618.01 -2.4536% MA 538.03 -0.4772%
AAPL 219.385 0.6815% MSFT 368.125 -2.8181% NVDA 104.65 -4.5774% GOOGL 151.81 -1.6329% GOOG 153.5424 -1.6132% AMZN 185.6 -3.6945% META 562.118 -2.5353% AVGO 162.44 -3.9499% LLY 804.38 -2.2042% TSLA 248.55 -5.6915% TSM 163.325 -1.1649% V 341.81 -0.3033% JPM 240.93 -0.7906% UNH 523.0 1.3487% NVO 67.85 -0.5144% WMT 86.585 1.6853% LVMUY 123.35 -2.4747% XOM 119.62 1.6054% LVMHF 618.01 -2.4536% MA 538.03 -0.4772%

small-cap

One NYSE- Listed Biotechnology Stock Under Radar- PTN

Mar 26, 2025 | Team Kalkine
One NYSE- Listed Biotechnology Stock Under Radar- PTN
Image source: shutterstock

PTN:NYSE
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (US$)

Palatin Technologies, Inc

Palatin Technologies, Inc (NYSE: PTN) is a biopharmaceutical company focused on developing medicines that influence the melanocortin receptor system. It specializes in creating targeted, receptor-specific therapies for diseases with unmet medical needs and strong commercial potential. The company's research primarily centers on MC1r agonists, which have the potential to treat inflammatory and autoimmune conditions, including dry eye disease (keratoconjunctivitis sicca), uveitis, diabetic retinopathy, and inflammatory bowel disease.

Positive Growth Prospects

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.